WEGOVY 4 MG / 3 ML
SEMAGLUTIDE : 4 MG / 3 ML · DIN 02528525 · NOVO NORDISK CANADA INC
Health Canada status: MARKETED
What is WEGOVY?
WEGOVY 4 MG / 3 ML contains SEMAGLUTIDE : 4 MG / 3 ML. It is listed in the Health Canada Drug Product Database under DIN 02528525, held by NOVO NORDISK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 28-Mar-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is WEGOVY used for?
WEGOVY® is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity. It is also indicated for pediatric patients aged 12 to less than 18 years with an initial BMI at the 95th percentile or greater for age and sex, a body weight above 60 kg, and an inadequate response to reduced calorie diet and physical activity alone. Additionally, WEGOVY® is indicated to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI equal to or greater than 27 kg/m², and for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02528525 |
|---|---|
| Brand name | WEGOVY |
| Generic / active ingredient | SEMAGLUTIDE : 4 MG / 3 ML |
| Manufacturer | NOVO NORDISK CANADA INC |
| Strength | 4 MG / 3 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | A10BJ06 SEMAGLUTIDE |
| AHFS class | 68:20.06 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Mar-2024 |
| Original market date | 2024-03-28 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Single-use pre-filled pen delivering doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg. Multi-use pre-filled pen (FlexTouch®) delivering doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg.
Is SEMAGLUTIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by DR REDDY'S LABORATORIES LTD (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A10BJ06 SEMAGLUTIDE. 9 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OZEMPIC | 0.68 MG | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02540258 |
| OZEMPIC | 1.34 MG | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02471469 |
| RYBELSUS | 1.5 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | DIN 02551012 |
| RYBELSUS | 14 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | DIN 02497611 |
| RYBELSUS | 3 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | DIN 02497581 |
| RYBELSUS | 4 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | DIN 02551020 |
| RYBELSUS | 7 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | DIN 02497603 |
| RYBELSUS | 9 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | DIN 02551039 |
| OZEMPIC | 1.34 MG | SOLUTION | NOVO NORDISK CANADA INC | DORMANT | DIN 02471477 |
| OZEMPIC | 2.68 MG | SOLUTION | NOVO NORDISK CANADA INC | APPROVED | DIN 02523930 |
Who else supplies SEMAGLUTIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SEMAGLUTIDE appears in 152 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.